Celon has entered into a joint venture with Aurobindo Pharma to develop, manufacture and market highly innovative and niche Hormonal & Oncology generic formulations for the regulated markets. These generic formulations will be marketed under a special purpose vehicle-‘Eugia Pharma Specialities’.

Our strong product development capabilities, state-of-the-art manufacturing and robust quality management systems have equipped us with the confidence to launch high quality generics in key markets. Our transparent and strong relationships with pharmacy chains and other distributor networks will help us deliver value & service to customers and patients globally.

In the unbranded generics space, our constant endeavour will be to scale up the value chain in the marketing of our products. Further, we are determined to bring in increased revenues from our technology driven products.

We are determined to leverage every opportunity to extend our high-quality products to more people around the world

Our generic product offerings will be focused on the following therapy areas:

  • Hormones
  • Oncology

We are committed to deliver quality generics with cost advantage in highly regulated markets such as

  • United States
  • European Union
  • South Africa
  • Australia
  • Brazil